The Potential of panHER Inhibition in Cancer
Authors:
Open Access
- 28 January 2015
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 5, 2
Abstract
Purpose: Hyper-activation of the HER (erbB) family receptors, HER 1-4, leads to up-regulation of the three vital signaling pathways: mitogen activated protein kinase, phosphoinositide 3-kinase/AKT, and Janus kinase/signal transducer and activator of transcription pathways. Blocking HER1/EGFR has a limited anticancer effect due to either secondary mutation e.g., T790M or by-pass signaling of other HER members. The emergence of an anti-panHER approach to blockade of these pathways as a cancer treatment may provide a solution to this resistance. This review aimed to provide an overview of the HER signaling pathways and their involvement in tumor progression and examine the current progress in panHER inhibition. Methods: Recent literature associated with HER signaling pathways and panHER inhibition was reviewed through PubMed and Medline database, followed by critical comparison and analysis. Results: Pre-clinical studies and clinical trials of panHER inhibitors show promising results, and the potential to improve patient outcomes in solid cancers. Conclusion: The use of panHER inhibitors in cancers with HER-family hyper-activation, such as other epithelial cancers and sarcoma, is a new direction to research and has potential in clinical cancer therapy in the future.Keywords
This publication has 115 references indexed in Scilit:
- A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumorsInvestigational New Drugs, 2012
- Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumorsInvestigational New Drugs, 2012
- A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancerBreast Cancer Research and Treatment, 2012
- Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumorsInvestigational New Drugs, 2012
- Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cellsBritish Journal of Cancer, 2011
- Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitorOncogene, 2010
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene, 2008
- Targeting HER proteins in cancer therapy and the role of the non-target HER3British Journal of Cancer, 2007
- EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitorsCritical Reviews in Oncology/Hematology, 2007
- EGF–ERBB signalling: towards the systems levelNature Reviews Molecular Cell Biology, 2006